REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy aims to fight back against stubborn blood cancer
Disease control TerminatedThis study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this two-drug approach can help control the cance…
Matched conditions: REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC